Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Axsome is also conducting the ACCORD-2 study, a Phase 3, double-blind, placebo-controlled, randomized withdrawal trial evaluating the efficacy and safety of AXS-05 in AD agitation. The enrollment target for the ACCORD-2 trial has been met and the Company now anticipates topline results in the second half of 2024. Read More

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Ads Links by Easy Branches
Play online games for free at games.easybranches.com
Guest Post Services www.easybranches.com/contribute
40th edition of Festival Innu Nikamu | July 30th to August 4th, 2024
Commodities Face Contagion as Global Market Meltdown Deepens